Following the treatment with the DNA methylation inhibitor 5′-nitropyrimidine, the expression of CBL-c, an epigenetic demethylation target, can be enhanced in non-small cell lung cancer (NSCLC). The gene discussed is CBLC; the disease is non-small cell lung carcinoma.